Results 221 to 230 of about 17,985,271 (268)
Some of the next articles are maybe not open access.
Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension
New England Journal of Medicine, 2009A 46-year-old-woman presents with exertional dyspnea and syncope and receives a diagnosis of idiopathic pulmonary arterial hypertension. Treatment with sildenafil is recommended. Sildenafil and tadalafil are phosphodiesterase type 5 inhibitors that ameliorate pulmonary arterial hypertension by increasing levels of cyclic guanosine monophosphate in the ...
Stephen L, Archer +1 more
openaire +2 more sources
FR226807: a potent and selective phosphodiesterase type 5 inhibitor
European Journal of Pharmacology, 2001We describe the pharmacological characteristics of a novel phosphodiesterase type 5 inhibitor FR226807, N-(3,4-dimethoxybenzyl)-2-[[(1R)-2-hydroxy-1-methylethyl]amino]-5-nitrobenzamide. FR226807 inhibited phosphodiesterase type 5 isolated from human platelets with an IC(50) value of 1.1 nM. FR226807 also inhibited phosphodiesterase type 6 with an IC(50)
N, Hosogai +12 more
openaire +2 more sources
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension
Advances in Therapy, 2009Pulmonary arterial hypertension (PAH) is a rare disease characterized by vascular proliferation and remodeling, resulting in a progressive increase in pulmonary arterial resistance, right heart failure, and death. The pathogenesis of PAH is multifactorial, with endothelial cell dysfunction playing an integral role.
David, Montani +8 more
openaire +2 more sources
The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction
Expert Opinion on Drug Safety, 2016Phosphodiesterase type 5 inhibitors (PDE5Is) are the leading drugs for the treatment of erectile dysfunction (ED), being recommended as a first line treatment by both the European and US urological guidelines. PDE5Is are highly effective as compared to placebo, well tolerated and have a very low, though not negligible, rate of severe treatment-related ...
Ventimiglia Eugenio +3 more
openaire +2 more sources
Phosphodiesterase Type 5 Inhibitor Abuse: A Critical Review
Current Drug Abuse Reviewse, 2011Abuse of sildenafil has been reported since its introduction in 1999 and commonly documented in combination with illicit drugs among men and women of all ages. Increased risks of sexually transmissible diseases including HIV have been associated with sildenafil use in men who have sex with men.
Gregory, Lowe, Raymond, Costabile
openaire +2 more sources
Phosphodiesterase Type-5 Inhibitors and Glaucoma
International Ophthalmology ClinicsPhosphodiesterase type-5 (PDE5) inhibitors are widely prescribed for erectile dysfunction and exert their pharmacologic effects through augmentation of nitric oxide–cyclic guanosine monophosphate signaling, a pathway with important ocular vascular implications.
Abdelrahman M. Elhusseiny +1 more
openaire +1 more source
Current Pharmaceutical Design, 2005
Erectile function is determined by tight regulation of relaxation or contraction of corpus cavernosal smooth muscle, which is the result of a long and complex chain of molecular events. Control of erectile function resides in signaling pathways of the central and peripheral nervous system, as well as intracellular events in the penile smooth muscle ...
openaire +2 more sources
Erectile function is determined by tight regulation of relaxation or contraction of corpus cavernosal smooth muscle, which is the result of a long and complex chain of molecular events. Control of erectile function resides in signaling pathways of the central and peripheral nervous system, as well as intracellular events in the penile smooth muscle ...
openaire +2 more sources
Effects of phosphodiesterase type 5 inhibitors on Raynaud’s phenomenon
Rheumatology International, 2014Raynaud's phenomenon (RP) is commonly observed in fingers and toes of patients with connective tissue diseases (CTDs). However, existing vasodilators have very limited efficacy. In this study, phosphodiesterase type 5 inhibitors (PDE-5Is) were administered to evaluate efficacy on RP.
Yasuyuki, Kamata, Seiji, Minota
openaire +2 more sources
Potency and selectivity of vardenafil: a phosphodiesterase Type 5 inhibitor
Expert Opinion on Drug Metabolism & Toxicology, 2005Erectile dysfunction (ED) is a widespread, age-related medical condition that affects > 50% of men aged 40 - 70 years. Pharmacotherapy with orally available phosphodiesterase 5 (PDE5) inhibitors offers a convenient and simple approach to treatment. Results of numerous clinical trials have demonstrated significant efficacy in restoring the ability to ...
openaire +2 more sources
Phosphodiesterase Type 5 Inhibitors: State of the Therapeutic Class
Urologic Clinics of North America, 2007With three effective and safe phosphodiesterase type 5 (PDE5) inhibitors, the clinician now has multiple choices in the treatment of patients who have erectile dysfunction of all severities and etiologies. Based on pharmacokinetics, pharmacodynamics, efficacy, and safety, each of these agents can be used.
openaire +2 more sources